Rights and Permissions
Oliver Ottmann, Giuseppe Saglio, Jane F. Apperley, Christopher Arthur, Eduardo Bullorsky, Aude Charbonnier, John F. Dipersio, Hagop Kantarjian, Hanna Jean Khoury, Dong-Wook Kim, Diane Healey, Lewis Strauss & Jorge E. Cortes. 2018. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal volume 8, Article number: 88 (2018). doi: 10.1038/s41408-018-0122-3. https://www.nature.com/articles/s41408-018-0122-3.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Ottmann, Oliver; Saglio, Guiseppe; Apperley, Jane F.; Arthur, Christopher; Bullorsky, Eduardo; Charbonnier, Aude; Dipersio, John F.; Kantarjian, Hagop; Khoury, Hanna Jean; Kim, Dong-Wook; Healey, Diane; Strauss, Lewis; and Cortes, Jorge E., ,"Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib." Blood Cancer Journal.8,9. 88. (2018).